Next-generation sequencing (NGS) is a DNA sequencing technology, which has emerged as a vital element in genomic research. It is gaining prominence as an everyday research tool among researchers to study biological systems at a more rapid pace than conventional sequencing methods such as Sanger sequencing.
Read full research report at :
Utilization of the NGS technology in IVD systems for clinical applications is likely to witness a sharp rise. For instance, in November 2017, Illumina, Inc. announced the launch of its NextSeq™ 550Dx instrument, a CE-IVD marked and FDA-regulated NGS system for the development of an array of IVD assays.
Lower Turnaround Time to Make Targeted Sequence a Highly Preferred Product
Next-generation sequencing is used to describe a number of different modern sequencing technologies, including targeted sequencing, transcriptome sequencing, and exome sequencing. Demand for targeted sequence is likely to remain high for coming years. Declining sequencing costs and rising awareness regarding its advantages such as manageable data sets and lower turnaround time can contribute to the growth of the segment. Increasing number of projects being undertaken pertaining to protein expression analysis is translating into the greater uptake of targeted sequencing. Soaring need for analysis of smaller dataset can also supplement the growth of the segment.
Adoption rate of exome sequencing is likely to increase at a noteworthy pace in the near future. The growth of the segment can be attributed to rising research and development activities aimed at mapping human and non-human genomes. Uptake of exome sequencing is high for the study of rare Mendelian disorders as it is an effective way to detect genetic variants in the genes of an individual. Rapid technological advancements will also benefit the growth of the segment.
Increasing efforts by companies to boost awareness regarding NSG services and products through workshops and seminars can escalate the growth of the next-generation sequencing (NGS) market. Rising R&D activities promoting advancements in the field of metabolomics, transcriptomics, and proteomics are likely to provide a fillip to the market. Genomics and proteomics operate with the help of extensive structural information that needs to be gathered and arranged by means of determination of sequence and subsequent integrated data analysis.
As per the findings of a report added to Radiant Insights, Inc.; Asia Pacific is likely to remain a promising region during the forecast period (2017 to 2021). Improving healthcare infrastructure is anticipated to drive the market in the region. Some of the prominent companies in the market are CapitalBio Corporation, Thermo Fisher Scientific, Berry Genomics Co. Ltd., Roche, and Qiagen.
To get free sample request at :